Project Description:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability
To evaluate the efficacy, safety, and tolerability of
brexpiprazole in reducing irritability in children and
adolescents ages 5 to 17 years with a diagnosis of ASD.